Magdalena Plebanski

Ethics in biomedical research

Abstract available soon

Professor Magdalena Plebanski

Director: Biomedical and Health Innovation Enabling Capability Platform
Head: Translational Immunology and Nanotechnology Program, School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia

PhD (Immunology), MBA (Business), DPS (Psychology), BScHon (Biomedicine). NHMRC Senior Research Fellow. Director of the Biomedical and Health Innovation Enabling Capability Platform (BHI-ECP) at RMIT University, as well as Head of the Translational Immunology and Nanotechnology Program at School of Health and Biomedical Sciences at RMIT. Interdisciplinary research leader in nanotechnology for biomedical innovation, leveraging exciting cross-disciplinary collaborations with engineers and clinicians to develop new approaches to promote human health. Primary interest is to develop practical immune therapies and vaccines against complex diseases, specifically cancer, malaria and asthma, pioneering the use of synthetic size-defined non-inflammatory nanoparticles. >220 publications including >190 full-lengh peer-reviewed publications including field changing findings on vaccines, and on immune evasion mechanisms used by parasites and cancer cells including top world-class journals, Science, Nature, Nature Biotechnology, Immunity, Nature Medicine, Plos Pathogens, PNAS, Nature Communications and Lancet, to name a few. Currently studying immunity in multiple large scale Phase I and Phase II human trials: of vaccines in the elderly or to validate new diagnostics, prognostics and treatments for ovarian cancer, together with Charitable Organizations, Universities, Hospitals and large Pharma. Around 40 patents in 10 patent families. Successfully progressed findings into human trials or commercialization in diverse roles as inventor, CSO, CEO and Director in biotechnology companies nationally and internationally. Current interests further involve big data analysis for the optimized application of vaccines and chemotherapy (personalized medicine or precision medicine) to vulnerable populations such as the elderly, as well as to patients with cancer, as well as the promotion of holistic, integrated, compassionate approaches to human health.